Agilent Technologies, Inc. (A) Deep Value Intelligence Report

Intelligence Summary#

Thesis + Conditions#

Core Thesis: EXECUTIVE SUMMARY Agilent (A) is an elite, wide-moat compounder with exceptional business economics (16.2% ROIC, 52.4% gross margin). However, at $149 (30x forward P/E), it is priced for near-perfection, leaving a negligible traditional margin of safety.

Key Risks: - The Bull (Risky): Agilent's "toll bridge" regulatory moat and sticky lab workflows justify a premium multiple. The shift toward asset-light software and oncology diagnostics, coupled with a biopharma capex rebound, means waiting for a 22x P/E is a recipe for missing a massive compounding rally. - The Bear (Safe): A 30x P/E yields just 3.3%, offering no equity risk premium over risk-free rates. If historical mid-single-digit organic growth persists, or if Chinese market headwinds prove structural rather than cyclical, the downside is severe. Furthermore, executing share buybacks at 30x earnings destroys shareholder value. - The Pragmatist (Neutral):** Both extremes are flawed. Demanding 22x on an elite 16.2% ROIC compounder guarantees missed opportunity, but ignoring the 30x multiple risks a severe drawdown. The solution is a "toe-hold" starter position to capture recovery momentum while preserving capital to average down if valuation compresses.

Confidence: Medium

Analyst Team Reports#

Fundamentals Analysis#

Latest Earnings Snapshot#

Most recent reported quarter anchored on 2026 Q2, with prior-year comparison when available.

Key Takeaways: This snapshot anchors the most recent reported quarter before the narrative analysis. It helps readers separate long-run business quality from whatever changed in the latest earnings print.

17-Year Financial Metrics for A#

All values below are computed deterministically from raw data - not estimated by AI.

Issuer profile: operating company (Healthcare / Diagnostics & Research).

17-Year Financial Metrics#

Annual rows come from reported financial statements. The final TTM row is computed from the latest four quarters.

Profitability Metrics#

• Return on Equity (ROE): 19.3%
• Return on Invested Capital (ROIC): 16.2%
• Return on Assets (ROA): 10.2%
• Gross Margin: 52.4%
• Operating Margin: 21.3%
• Net Profit Margin: 18.8%

Liquidity Metrics#

• Current Ratio: 1.96
• Quick Ratio: 1.40

Leverage Metrics#

• Debt-to-Equity Ratio: 0.50
• Interest Coverage Ratio: 13.21
• Net Debt: $1.56B

Growth Metrics (Year-over-Year)#

• Revenue Growth: 6.7%
• Net Income Growth: 1.1%
• Free Cash Flow Growth: -16.1%
• Revenue CAGR (3-Year): 0.5%
• Revenue CAGR (5-Year): 5.4%

Valuation Metrics#

• P/E Ratio (TTM): 29.98
• Forward P/E: 22.58
• Price-to-Book: 5.92
• Price-to-Sales: 5.83
• PEG Ratio: 1.31
• EV/EBITDA: 21.79
• Free Cash Flow Yield: 2.7%
• Earnings Yield: 3.3%

Owner Earnings (Buffett Method, Code-Computed)#

• Net Income: $1.30B
• • Depreciation & Amortization: $288.0M
• • Capital Expenditures: $-407.0M
• • Working Capital Changes: $-131.0M
• = Owner Earnings: $1.43B

Intrinsic Value (Code-Computed)#

• Current Price: $149
• Headline Intrinsic Value (business-model routed): $71 Business model: operating company - weighted blend [Damodaran FCFF + reverse-DCF fair + owner-earnings DCF] (operating_company) Model spread (min-max across DCFs): $43 - $95 Margin of safety vs. price (headline): -111.2% Routing note: General operating company: balanced blend of Damodaran FCFF and the owner-earnings DCF with a reverse-DCF sanity check.
• Buffett Method (Owner Earnings): Conservative: $18 Average: $95 Optimistic: $308
• Cash Flow Method (FCF): Conservative: $28 Average: $62 Optimistic: $241
• Damodaran FCFF (WACC + margins + reinvestment): Conservative: $32 Average: $43 Optimistic: $61 Monte Carlo band (P10-P90): $34 - $58 (median $44) P(intrinsic value > price): 0.0%
• Reverse-DCF: price implies ~18.6%/yr owner-earnings growth for 10y; trailing 3y was -6.6%, 5y 19.0%.

Piotroski F-Score: 5/9#

• Positive Net Income: PASS
• Positive Operating Cash Flow: PASS
• ROA Improvement: FAIL
• Cash Flow > Net Income: PASS
• Decreasing Debt: PASS
• Improving Current Ratio: FAIL
• No Dilution: PASS
• Improving Gross Margin: FAIL
• Improving Asset Turnover: FAIL

ANALYST STANCE: AVOID

Agilent Technologies Inc. (A) - Buffett-Style Fundamental Analysis#

Agilent is a high-quality healthcare tools, diagnostics, and laboratory-services business with durable customer relationships, recurring service revenue, and attractive profitability. The problem is not business quality; the problem is valuation. At $149 per share, the stock trades far above the deterministic intrinsic value anchor of about $71 per share, with the model spread ranging from roughly $43 to $95. A Buffett-style investor would likely admire the franchise but reject the current price because the margin of safety is deeply negative.

---

Revenue Breakdown#

Key Takeaways: Agilent's largest revenue source remains Life Sciences and Applied Markets, which supplies analytical instruments and workflow solutions to pharma, chemical, environmental, food, and academic customers. CrossLab is strategically important because service, consumables, and support revenue tend to be more recurring and resilient than instrument sales. Diagnostics and Genomics adds exposure to oncology, pathology, companion diagnostics, and molecular testing, supporting Agilent's long-term healthcare moat.

---

Current vs. 10-Year Historical Average#

10-year average uses fiscal years 2016-2025. Current values use 2026 TTM where available, except valuation metrics that reflect the current market price.

Key Takeaways: Agilent's profitability metrics are better than average, with ROE, EPS, net income, and margins all above their 10-year norms. However, the valuation is not cheap: the share price and market cap are far above historical averages while revenue and free cash flow growth have slowed. The most important tension is that business quality remains high, but the market price already discounts a very optimistic future.

---

Market Metrics Interpretation#

Agilent's current market price of $149 and market capitalization of about $42.25B are well above the company's 10-year averages. The stock has benefited from durable demand in analytical instruments, life sciences, diagnostics, and lab services, but the current valuation appears to assume sustained high-quality compounding.

The P/E ratio of 29.98x is below Agilent's 10-year average of 35.64x, but this does not make the stock automatically cheap. Several historical years had elevated P/E ratios because of temporary earnings compression or market enthusiasm. On an absolute basis, a near-30x earnings multiple requires either strong durable growth, further margin expansion, or both.

The P/B ratio of 5.93x is almost exactly in line with the 10-year average of 5.88x. However, for a healthcare tools and diagnostics operating company, book value is not the best valuation anchor. Agilent's value is driven more by installed base, service relationships, intellectual property, workflow integration, brand reputation, and free cash flow generation than by tangible book value. Therefore, a Buffett-style valuation should rely primarily on owner earnings and discounted cash flow, not on P/B alone.

---

Profitability Analysis#

Agilent's profitability profile is strong. ROE of 19.9% and ROIC of 16.1% indicate that the business earns attractive returns on capital. ROIC is especially important from a Buffett perspective because it shows the company can generate economic value above its cost of capital without requiring excessive leverage.

The company's gross margin is 52.7%, below the early-decade 60%+ levels but broadly stable in the low-to-mid 50% range since 2016. This suggests a business mix that is still attractive but not immune to product mix shifts, competition, and input-cost pressure. Operating margin of 21.5% is above the 10-year average of 19.4%, showing improved cost discipline and scale benefits.

Net income of $1.41B and net margin of 19.6% are both above historical averages. This is a positive quality signal. The concern is that margins are already high, which limits the room for easy future upside unless revenue growth accelerates or mix improves further toward services, consumables, and diagnostics.

---

Growth Analysis#

Agilent's growth profile is respectable but not currently strong enough to justify the prevailing market price under a conservative value framework. Revenue growth is 4.1% TTM, below the 10-year average of 5.8%. The company has had strong rebound periods, especially around 2021, but the most recent multi-year trajectory is more moderate.

Net income growth of 8.5% TTM is better than revenue growth, showing operating leverage and cost control. However, the 10-year average net income growth rate is distorted by volatile rebound years, including large increases after depressed earnings periods.

The most concerning growth metric is free cash flow growth of -5.6% TTM, following a decline in 2025 as well. Free cash flow remains healthy in absolute terms at $1.09B, but the trend is not strong enough to support a valuation that requires very high future owner-earnings growth.

---

Balance Sheet and Financial Strength#

Agilent's balance sheet is solid. Total assets are $13.06B, shareholders' equity is $7.12B, and cash and equivalents are $1.81B. Total debt is $3.35B, resulting in a debt-to-equity ratio of 0.47x, slightly below the 10-year average of 0.48x.

The company's interest coverage ratio of 13.21x indicates that debt service is not a major near-term concern. Net debt of about $1.56B is manageable relative to operating income and cash flow. From a Buffett perspective, Agilent passes the financial-strength test: it is not overleveraged, has adequate liquidity, and has the flexibility to reinvest, acquire, repurchase shares, and pay dividends.

The issue is not solvency. The issue is whether the current market price provides enough margin of safety.

---

Cash Flow and Dividend Policy#

Agilent generated $1.09B of TTM free cash flow, slightly above its 10-year average of about $1.03B but below the stronger years of 2021, 2023, and 2024. The company's FCF margin of 15.0% is solid, though below the recent peak levels above 20%.

The dividend is modest but growing. Dividends per share are $1.01 TTM, up from $0.81 in 2022. Agilent only began paying dividends in the dataset period starting in 2022, so the dividend track record is short. The payout appears sustainable, but Agilent remains more of a reinvestment-and-capital-appreciation business than an income stock.

A Buffett investor would likely prefer Agilent to prioritize high-return reinvestment, disciplined bolt-on acquisitions, and opportunistic buybacks only when the stock trades below intrinsic value. At the current valuation, aggressive buybacks would be less attractive.

---

Buffett-Style Economic Moat Assessment#

Agilent has a credible economic moat, though not an unassailable monopoly. Its moat comes from several sources:

Key Takeaways: Agilent's moat is real and supported by switching costs, customer trust, regulatory complexity, and recurring service revenue. The business should remain durable over a long horizon. However, a durable moat does not automatically justify paying any price, especially when cash-flow growth is currently soft.

---

Three-Scenario Buffett-Style Owner Earnings DCF#

Starting owner earnings: $1.43B Estimated shares outstanding: approximately 283.6M, calculated from $42.25B market cap divided by $149 share price Discount rate: 10% Terminal growth rate: 2.5% Terminal value formula: Year 10 Owner Earnings x 1.025 ÷ (10.0% - 2.5%) Valuation basis: Equity owner earnings; used as a sanity check against the deterministic model-based intrinsic value.

Key Takeaways: Even the optimistic hand-built owner-earnings DCF produces an estimated value of only about $106 per share, well below the current $149 price. The conservative case is close to the deterministic headline intrinsic value of roughly $71. This means the stock requires stronger and more persistent owner-earnings growth than the conservative or base-case assumptions support.

---

Intrinsic Value Cross-Check#

Key Takeaways: The strongest model-based anchor is the headline intrinsic value of about $71, supported by a core spread of roughly $43 to $95 across major DCF approaches. The current price of $149 sits well above these valuation ranges. The Damodaran FCFF model is especially cautious, suggesting that the market price is difficult to justify using normalized margins, reinvestment, and cost-of-capital assumptions.

The reverse-DCF is the clearest warning sign: the current price implies approximately 18.6% annual owner-earnings growth for 10 years. That is a demanding hurdle. Agilent's trailing 3-year owner-earnings growth was negative, while the 5-year figure was strong but likely helped by cycle timing and post-pandemic recovery dynamics. A Buffett investor would usually avoid situations where the investment thesis depends on near-perfect execution.

---

Management and Capital Allocation#

Agilent's management has performed well operationally. ROE and ROIC are attractive, margins have improved, and the balance sheet remains healthy. The company has also introduced and grown a dividend, while maintaining flexibility for reinvestment and acquisitions.

The main capital-allocation concern is valuation-sensitive buybacks. If repurchases occur at prices materially above intrinsic value, they may destroy rather than create shareholder value. Buffett's framework rewards buybacks only when shares are clearly undervalued. At the current market price, buybacks would need to be highly selective.

The dividend policy is conservative and sustainable. However, the dividend yield is not high enough to compensate investors for valuation risk.

---

Key Investment Insights#

Key Takeaways: Agilent has many of the traits Buffett investors like: durable demand, strong returns on capital, recurring revenue, and a conservative balance sheet. But valuation overwhelms quality at the current price. The stock looks priced for a level of growth that is not supported by recent free cash flow trends.

---

Red Flags#

Key Takeaways: The biggest red flag is valuation, not financial distress. Agilent's balance sheet is sound and the business is durable, but the market price assumes a very favorable future. Weak recent free cash flow growth makes that valuation harder to defend.

---

Opportunities#

Key Takeaways: Agilent has attractive long-term growth avenues, especially in services, diagnostics, and regulated life sciences workflows. If end-market demand improves and management continues to expand recurring revenue, the company can compound value. The challenge is that much of this opportunity appears already capitalized into the current stock price.

---

Final Investment Stance: AVOID#

Agilent is a strong company, but the current valuation does not provide a Buffett-style margin of safety. The business has durable competitive advantages, attractive returns on capital, stable margins, and a healthy balance sheet. However, the stock price of $149 is far above the deterministic headline intrinsic value of about $71, and above the core valuation spread of approximately $43 to $95.

For a long-term value investor, the appropriate conclusion is:

Key Takeaways: Agilent is the kind of business worth following closely, but the stock is not currently priced for conservative value investors. The implied growth expectations are too high relative to recent revenue and free cash flow trends. A Buffett-style investor should wait for a materially lower price or much stronger evidence that owner earnings can compound at a high-teens rate for many years.

Fundamental Visuals#

This graph tracks the profitability and return metrics (ROE, ROIC, Margins) of A over the past decade, highlighting capital efficiency trends.

This chart illustrates the financial health of A over the last 10 years, mapping cash equivalents and free cash flow against total obligations (Debt).

---

Intrinsic Value Analysis (Buffett)#

Following Warren Buffett's value investing philosophy: Circle of Competence, Economic Moat, Management Quality, and Margin of Safety.

Intrinsic Value Snapshot#

Price is what you pay. Intrinsic value is what the business may be worth based on the cash it can create for owners over time. We show a range, not one magic number.

• Current Price: $149.29
• Value Range (conservative to optimistic across both DCF methods): $17.87 to $308.03

Owner Earnings (Buffett Method)

• Net Income: $1,303,000,000.00
• Depreciation & Amortization: $288,000,000.00
• Capital Expenditures: $-407,000,000.00
• Working Capital Changes: $-131,000,000.00
• Owner Earnings: $1,434,000,000.00

Intrinsic Value

Buffett Method

Uses owner earnings. Stricter, and usually more conservative. - Conservative: $17.87 - Average: $95.01 - Optimistic: $308.03 - Discount Rate: 10.0%

Cash Flow Method

Uses free cash flow. Better for companies spending heavily today to grow tomorrow. - Conservative: $27.87 - Average: $61.63 - Optimistic: $241.04 - Discount Rate: 10.0%

ANALYST STANCE: WATCH

Agilent Technologies (A) - Buffett-Style Investment Review#

Agilent is a high-quality life-sciences and diagnostics tools company with durable customer relationships, attractive gross margins, and a meaningful installed-base moat. The business is understandable and economically strong, but the current stock price embeds growth expectations that are too demanding relative to recent cash-flow performance. This is the kind of business worth owning at the right price, but not at today's valuation.

---

1. Factor Scorecard#

Key Takeaways: Agilent scores well on business quality, moat, and understandability. The hard solvency floor is not an issue. The major weakness is not the company itself, but the price investors are currently being asked to pay.

---

2. Moat Analysis#

Key Takeaways: Agilent's moat is real and primarily comes from trust, installed base, validated workflows, and switching costs. This is not a commodity equipment seller; recurring service and consumables revenue improve durability. The moat is wide and stable, though not as dominant as the very best platform businesses.

---

3. Management Quality Assessment#

Agilent's management has historically operated the company with discipline. The business has maintained high gross margins, solid returns on equity, and meaningful free cash flow despite cyclicality in life-science tools demand. Capital allocation has included internal reinvestment, bolt-on acquisitions, dividends, and repurchases.

The positive point is that management has not run the company like a fragile roll-up or a heavily levered financial engineering story. The caution is that Agilent is not founder-led or owner-operated, and buybacks at elevated multiples create less value than buybacks at depressed prices. From a Buffett perspective, management is competent and rational, but not exceptional enough to overcome an obviously stretched valuation.

---

4. Financial Summary#

Key Takeaways: Agilent has produced consistently good margins and returns, with ROE around 20% in recent years. Revenue growth has been uneven, showing that this is not a straight-line compounder. The current valuation is expensive relative to free cash flow, with only a 2.7% FCF yield.

---

5. Owner Earnings Calculation#

Using Buffett's preferred owner-earnings framework:

Key Takeaways: Agilent is genuinely cash-generative, but the current owner-earnings yield is modest. At roughly $4.02 of owner earnings per share against a $149 stock price, investors are paying a high multiple for a good but not hyper-growth business. That makes valuation discipline especially important.

---

6. Three-Scenario DCF Valuation#

Key Takeaways: The valuation range is wide because small changes in growth assumptions matter greatly at this price. Even the more optimistic scenario remains well below the current $149 share price. The headline intrinsic value estimate of about $71 suggests the stock is materially overvalued today.

---

7. Margin of Safety Analysis#

Key Takeaways: The market is pricing Agilent as if it can compound at a very high rate for a decade. That is a demanding assumption for a company currently growing revenue in the mid-single digits and coming off an uneven three-year period. For a wide-moat business, a small discount may be enough, but here there is no discount at all.

---

8. Final Buffett Scorecard#

Key Takeaways: Agilent is a good business with durable economics, but valuation severely reduces the investment score. The company clears the quality bar but fails the price discipline test. This is a classic Buffett-style watchlist name: admirable business, unattractive entry price.

---

9. Investment Stance#

Stance: WATCH Conviction Level: High

Agilent is a high-quality analytical instruments and diagnostics business with a real moat, strong margins, and recurring revenue characteristics. It deserves a place on a long-term quality watchlist.

However, at $149 per share, the stock appears priced for near-perfect execution. The reverse DCF implies roughly 18.6% annual growth for a decade, which is too aggressive given current mid-single-digit revenue growth and recent uneven cash-flow trends. A more attractive entry point would require either a materially lower share price or clear evidence that Agilent can reaccelerate durable owner-earnings growth well above current expectations.

Buffett-style conclusion: Wonderful enough to study, too expensive to buy.

Valuation Bridge#

This bridge places the current market price beside each intrinsic value lens so readers can see whether upside depends on one method or shows up across several methods.

Key Takeaways#

If one method is far above the others, the upside case depends on a specific modelling assumption. When several methods cluster together, the valuation story is more robust.

Valuation Visuals#

This comparison chart from Latest Earnings Snapshot stacks current figures against historical benchmarks for A, making it easy to see where the company trades relative to its own averages.

This comparison chart from Current vs. 10-Year Historical Average stacks current figures against historical benchmarks for A, making it easy to see where the company trades relative to its own averages.

This comparison chart from Margin of Safety Analysis stacks current figures against historical benchmarks for A, making it easy to see where the company trades relative to its own averages.

The following chart maps the A Owner Earnings DCF valuation scenarios (Conservative, Average, Optimistic) to visually represent the margin of safety based on intrinsic value calculations.

This comparison chart from Lynch Classification stacks current figures against historical benchmarks for A, making it easy to see where the company trades relative to its own averages.

---

Trend & Growth Analysis (Lynch/Druckenmiller/Fisher)#

Following Peter Lynch's GARP, Stanley Druckenmiller's macro-aware approach, and Philip Fisher's scuttlebutt methodology.

ANALYST STANCE: WATCH

Agilent Technologies "A" Growth Investment Report#

Agilent is a high-quality life sciences tools and diagnostics company, but it does not currently screen as a Lynch-style fast grower. Revenue growth is mid-single-digit, valuation already discounts a much stronger growth future, and the current setup looks more like a durable stalwart than a ten-bagger candidate. I would watch for an inflection in diagnostics, oncology testing, biopharma demand, or margin expansion before advocating new growth capital.

---

1. Lynch Classification#

Key Takeaways: Agilent is a quality compounder, but it is not showing the 15% to 25% revenue growth profile that Lynch would classify as a fast grower. The stock carries a premium valuation despite only mid-single-digit revenue growth, which limits its attractiveness as a new growth investment today.

2. The Story in 3 Bullets#

• Agilent sells instruments, software, consumables, and diagnostics used by pharma, biotech, chemical, academic, and clinical labs.
• Its strongest long-term growth angles are biopharma research, oncology diagnostics, companion diagnostics, and increasingly data-driven lab workflows.
• The company benefits from recurring consumables and services, but the core instrument cycle remains exposed to lab budget cycles and slower biopharma capex periods.

3. TAM Analysis and 10x Test#

Key Takeaways: Agilent serves large and durable markets, but its existing scale makes a 10x revenue outcome difficult. The TAM is attractive, especially in diagnostics and biopharma workflows, but current growth does not suggest a near-term step-change toward ten-bagger economics.

4. Revenue Growth Trend#

Key Takeaways: The growth pattern is mixed. Agilent has shown strong longer-term growth over five years, but the more recent three-year trend is weak, and current revenue growth is only 6.7%. The market price appears to imply a significant reacceleration that is not yet visible in the available data.

5. Unit Economics#

Key Takeaways: Agilent is not best analyzed with SaaS-style LTV/CAC or net revenue retention metrics. The more relevant signals are gross margin, recurring consumables and services mix, ROE, and balance sheet strength. On those measures, the company looks financially high quality.

6. Inflection Point Assessment#

Key Takeaways: The most interesting potential inflection is in oncology diagnostics, especially companion diagnostic tests tied to targeted therapies. However, the available evidence points to an incremental growth driver rather than a confirmed company-wide growth acceleration. Guru buying is notable, especially Druckenmiller's initiation, but it is not enough by itself to override valuation and growth concerns.

7. Macro Setup#

Key Takeaways: Agilent has secular exposure to healthcare innovation and life sciences R&D, but parts of the business remain cyclical. A stronger biotech funding environment and lower rates would help. The macro setup is supportive but not powerful enough yet to create a high-conviction growth inflection.

8. Fisher 15 Points Score#

Key Takeaways: Agilent scores as a good Fisher company, mainly because of durable market exposure, strong margins, technical products, and recurring lab relationships. The score is not outstanding because the current data does not show a major growth acceleration, margin inflection, or exceptional ten-bagger runway from today's size.

9. Valuation Analysis#

Key Takeaways: Valuation is the biggest issue. A 30x earnings multiple and 2.7% free cash flow yield are hard to justify unless Agilent reaccelerates meaningfully. The reverse-DCF suggests the market is pricing in a growth profile much stronger than the current 6.7% revenue growth rate.

Key Takeaways: All three intrinsic value approaches sit materially below the current stock price. Even the most favorable owner-earnings model is well below $149. This makes the stock difficult to advocate for new money despite the company's quality.

10. Growth Investor Scorecard#

Key Takeaways: Agilent earns a WATCH rating because the business quality is strong, but growth and valuation do not clear the bar for an ADVOCATE stance. The company needs evidence of reacceleration before it becomes a compelling growth-stock idea.

11. Position Size Stance#

Key Takeaways: Agilent is not a sell-quality business, but it is not an obvious buy at the current valuation. Existing holders can monitor for diagnostics and biopharma recovery, while new investors should wait for a better price or clearer growth acceleration.

12. Key Risks and Catalysts#

Key Takeaways: The bull case depends on Agilent turning its diagnostics and life sciences exposure into faster organic growth. The bear case is simple: the company remains a mid-single-digit grower while the stock continues to trade at a premium multiple. That mismatch keeps the stance at WATCH.

Bottom Line#

Agilent is a strong company, but not currently a strong growth-stock setup. It has quality margins, durable end markets, and promising diagnostics exposure, yet the stock already prices in a much brighter growth future than the current numbers show. I would revisit if revenue growth accelerates, biopharma demand improves, or the stock corrects closer to intrinsic value.

Growth & Scorecard Visuals#

The radar chart below from Final Buffett Scorecard visualises how A ranks across weighted investment criteria. Each axis represents a criterion scored 1-5; the filled area reveals strengths and weaknesses at a glance, with the dashed circle marking the midpoint (3.0).

---

Market Technical Analysis#

ANALYST STANCE: WATCH

Agilent Technologies (A) Technical Report - Latest Trading Data Through 2026-08-13#

Current date is 2026-08-14, but it is not shown as a trading day in the retrieved data. The latest available close is $149.29 on 2026-08-13.

Agilent has shifted from a damaged first-quarter/early-second-quarter structure into a much stronger summer recovery. The stock bottomed near the $110-$115 zone in March-May, gapped sharply higher on 2026-05-28, then spent June digesting the move before re-accelerating in late July and early August. The current setup is technically constructive, but short-term risk/reward is less clean because price is extended above key moving averages and RSI is now in overbought territory.

---

Selected Indicators and Why They Matter#

Key Takeaways: The chosen indicators show a stock in a confirmed recovery phase, with price above short-, medium-, and long-term trend measures. Momentum is bullish, but RSI and proximity to the upper Bollinger Band suggest traders should be selective with new entries rather than chase strength blindly.

---

Trend Structure: Bullish, But Extended in the Short Term#

Agilent's trend alignment is currently favorable. The latest close of $149.29 is above the 10 EMA at $145.13, the 50 SMA at $135.33, and the 200 SMA at $130.64. This creates a bullish moving-average stack where price is leading, the short-term average is above the intermediate average, and the intermediate trend has moved above the long-term benchmark.

The stock has also reclaimed and held above the 200-day average, which is important because earlier in 2026 the stock traded meaningfully below that long-term line. The recovery from the March-May base is no longer just a bounce; it has matured into a trend repair. However, the current close is roughly 2.9% above the 10 EMA, 10.3% above the 50 SMA, and 14.3% above the 200 SMA, meaning the stock is no longer sitting at a low-risk trend support area.

Key Takeaways: Agilent's price is above all major moving averages, which supports a bullish technical backdrop. The issue is not trend quality, but entry quality: the stock has already moved far above its medium- and long-term averages, so fresh buying now carries elevated pullback risk.

---

Momentum: Strong, But Showing Early Signs of Cooling#

The MACD histogram is positive at +0.84, confirming that momentum remains bullish. It strengthened materially from negative readings in June and July, turned positive after the late-July breakout, and accelerated into early August. That supports the view that buyers regained control after the June pullback.

However, the histogram peaked recently near +0.92 on 2026-08-11 and has slipped to +0.88 on 2026-08-12 and +0.84 on 2026-08-13. This is not bearish by itself, but it does suggest upside momentum is no longer accelerating at the same pace. In a strong trend, this can simply mean consolidation; in an overbought setup, it can also precede a short-term pullback toward the 10 EMA.

RSI reinforces that message. The latest RSI is 71.44, after readings above 70 for several sessions. That is a classic overbought zone. Importantly, overbought does not mean "sell immediately" in a strong trend, but it does mean the probability of sideways digestion or a pullback has increased.

Key Takeaways: Momentum remains bullish, but the strongest acceleration may already have occurred. RSI above 70 argues against aggressive chasing and favors waiting for either a controlled pullback or a clean breakout with renewed volume.

---

Volatility and Bollinger Band Positioning#

The upper Bollinger Band is currently around $151.79, while the latest close is $149.29. Price recently pushed above the upper band on several sessions, including the move through the mid-$140s, but it is now back below the band as the band itself expands higher. This is typical of a strong breakout phase: price rides or briefly exceeds the upper band, then pauses while volatility envelopes adjust upward.

The ATR is 3.63, down from levels above 4.0 in late July. That means daily range volatility is easing even as price remains near highs. This can be constructive if it reflects orderly consolidation, but it also means traders should not assume the stock is low-risk; an ATR of $3.63 is still about 2.4% of the stock price, so a normal one-day move can be meaningful.

Key Takeaways: Agilent is trading close to its upper Bollinger Band, so upside continuation may require either a breakout above roughly $152 or a pause that allows the bands and moving averages to catch up. ATR has eased, which supports a more orderly trend, but volatility is still large enough that tight stops may be vulnerable.

---

Volume-Weighted Confirmation#

The VWMA is currently $141.80, well below the latest close of $149.29. This means price is trading above its volume-weighted trend level, which supports the bullish interpretation. In simple terms, the market's recent volume-weighted cost basis is below current price, so buyers from recent weeks are generally profitable.

The nuance is that the latest advance toward $150 has not been accompanied by a dramatic volume surge in the most recent sessions. Volume on 2026-08-13 was about 1.03 million, lower than several prior rally days. That does not invalidate the trend, but it suggests breakout confirmation above $150-$152 would be stronger if accompanied by expanding volume.

Key Takeaways: Volume-weighted trend support is bullish because price is well above VWMA. However, the latest push toward $150 has not shown overwhelming volume confirmation, so traders may want to see stronger participation before treating the move as a fresh breakout.

---

Key Trading Levels#

The most important upside area is the $150-$152 zone. The stock has recently traded near $150, and the upper Bollinger Band is around $151.79. A decisive close above this area would indicate continuation strength, especially if volume improves.

On the downside, the first support area is the 10 EMA near $145.13. A pullback into that zone could be healthy if price stabilizes there. Below that, the $141-$142 area, near VWMA and prior consolidation levels, becomes important. A break below that would suggest the short-term breakout is failing. Deeper trend support sits near the 50 SMA at $135.33, while the long-term line is near $130.64.

Key Takeaways: The cleanest bullish trigger is a strong close above $152 with better volume. The cleaner risk-controlled long setup may be a pullback toward $145-146 that holds, while a break below $141-142 would raise caution.

---

Tactical View#

The technical picture favors a bullish bias, but not an aggressive chase. Agilent has repaired its trend, reclaimed its long-term moving average, and built a bullish moving-average structure. Momentum is positive, and price is above VWMA, which means the recovery is supported by volume-weighted price behavior.

The reason for a WATCH stance rather than a straightforward ADVOCATE stance is short-term extension. RSI is overbought, price is near the upper Bollinger Band, and the latest volume does not yet confirm a decisive breakout through the $150-$152 area. Traders already long may consider trailing stops or partial risk management, while new buyers may prefer waiting for either a pullback toward the 10 EMA or a high-volume breakout above $152.

Key Takeaways: Agilent's chart is constructive, but the current location is not ideal for fresh aggressive entries. The best setups are either a disciplined pullback entry near short-term support or a confirmed breakout above $152 with stronger volume.

---

Options Market Analysis#

Reading options flow - put/call ratios, IV skew, and unusual activity - to gauge institutional positioning and event-driven risk.

ANALYST STANCE: WATCH

Options Market Report - Agilent Technologies Inc. A#

As of 2026-08-14, near-term options data for A shows very thin open interest, making the signal less reliable than for more liquid large-cap options chains. The strongest read is low-confidence bearish / defensive positioning, driven by put volume slightly exceeding call volume and materially higher put IV in the September expiry, but the lack of open interest and strike-level detail limits conviction.

---

1. Put/Call Ratio Analysis#

Key Takeaways: The put/call open interest ratio of 0.12 is far below the historical neutral baseline of roughly 0.7, suggesting the existing open positions are call-heavy rather than protective. However, the put/call volume ratio of 1.08 is above neutral, showing near-term trading flow has leaned more defensive or bearish. Because total OI is extremely low, this should be treated as a weak signal, not a strong institutional positioning read.

The contrast between call-heavy OI and put-heavy fresh volume may indicate traders are adding short-term hedges while the existing options book remains skewed toward calls. This is not a clean bullish setup; the fresher volume is more cautious.

---

2. Implied Volatility Assessment#

Key Takeaways: The September expiry shows a dramatic gap between put IV at 30.5% and call IV at 1.2%, which would normally imply meaningful downside fear or hedging demand. However, the extremely low call IV and limited OI suggest the IV data may be distorted by illiquidity or stale quotes. The safest interpretation is that puts are carrying the only meaningful volatility premium, but confidence is limited.

There is no catalyst information provided in the options dataset. Agilent often reports earnings around late fiscal-quarter windows, so if an earnings date falls before or near the September expiry, the put skew may reflect event-risk hedging. Without confirmed catalyst timing, this should be flagged as possible but not confirmed.

---

3. Unusual Options Activity#

Key Takeaways: No near-term contracts met the standard unusual activity threshold of volume greater than 5x open interest. That means there is no clean evidence of a fresh institutional sweep or large directional bet. The put-heavy aggregate volume is worth watching, but it is not enough by itself to call a strong smart-money signal.

Because open interest is so thin, even modest retail-sized trades can distort volume ratios. This reduces confidence in interpreting the flow as institutional hedging.

---

4. Open Interest Concentration and Gamma Levels#

Key Takeaways: Open interest is too low to identify meaningful pinning levels or gamma walls. The September call side has the most OI, but 66 contracts is not enough to create a strong gravitational level. This options chain does not currently show the kind of concentrated positioning that would likely dominate near-term stock movement.

Strike-level open interest was not provided, so specific max-pain or gamma-wall levels cannot be calculated. The best conclusion is that options positioning is not currently deep enough to provide strong price magnets.

---

5. Overall Options Sentiment Signal#

Key Takeaways: The options market signal for A is BEARISH with low confidence. The primary driver is the put-heavy near-term volume and the apparent put IV premium, suggesting traders are paying more attention to downside protection than upside speculation. However, extremely thin OI and potentially stale IV readings mean this is better viewed as a watch item than a decisive bearish options signal.

Final Read: BEARISH - Low Confidence#

The near-term options tape leans defensive: total put volume slightly exceeds call volume, the August and October expiries show put-heavy trading, and September puts carry much higher implied volatility than calls. That said, the existing open interest is call-heavy, no contract-level unusual activity was detected, and the entire chain appears illiquid.

Bottom line: options positioning suggests cautious downside concern, but the signal is not strong enough to treat as a high-conviction institutional bearish bet.

---

Summary Table#

Key Takeaways: The clearest options message is that recent flow is more cautious than bullish, even though existing open interest remains call-heavy. Put skew and put-heavy volume point to downside hedging, but the chain is too illiquid to support a high-conviction read. The appropriate stance is WATCH, not aggressive action based solely on options data.

Research Team Commentary#

The Research Manager synthesizes the Bull vs Bear debate into action-free commentary. This is a pre-risk view, not the final stance.

As a value portfolio manager applying an adaptive Warren Buffett framework, I've listened closely to both the bull and bear arguments for Agilent Technologies. Both analysts bring sharp insights to the table, and synthesizing their views requires us to balance the undeniable quality of the underlying business against the demanding realities of its current price.

To summarize the debate, the Bull rightfully points out that Agilent possesses a classic "toll bridge" moat. By embedding its instruments, software, and consumables into FDA-validated lab workflows, Agilent benefits from incredibly high switching costs and sticky, recurring revenue. With an ROIC of 16.2%, a 52.4% gross margin, and a shift toward an asset-light software and services model, the Bull argues that a 30x P/E is simply a fair price for a compounding machine positioned perfectly for long-term secular growth in life sciences.

On the other side, the Bear delivers a sobering reality check on valuation. While acknowledging Agilent's quality, the Bear correctly notes that a 30x multiple implies a reverse-DCF perpetual growth rate of 9 to 10%. For a company that historically grows at a mid-single-digit organic rate and faces cyclical headwinds like tightening biopharma budgets and structural sluggishness in China, that valuation leaves zero margin of safety. The Bear also raises a crucial capital allocation point: executing share buybacks at 30x earnings destroys shareholder value rather than creating it.

Here is my detailed investor commentary.

Core Takeaway Agilent is a quintessential high-quality, wide-moat franchise, but at a 30x forward earnings multiple, it is priced for near-perfection, leaving little to no traditional margin of safety for a new 10-year position. However, drawing on our recent hard-learned lessons, we must explicitly separate our long-term intrinsic value verdict from short-term tactical realities. Because the business fundamentals are rock-solid and the stock is exhibiting technical momentum in a "summer recovery," we should not aggressively short or avoid the name. The correct posture is a constructive hold for existing long-term investors, using valuation to control position sizing rather than to outright veto the stock's positive market structure.

Rationale From an adaptive value investing perspective, we prioritize business quality first, and Agilent passes this test with flying colors. A 16%+ ROIC and 50%+ gross margins generated from sticky, regulatory-validated lab workflows is exactly the kind of durable economic moat Buffett looks for. It is not a fragile business.

However, price is the ultimate determinant of return. A 30x P/E requires the company to flawlessly execute and accelerate its historical growth rate to justify the premium. As the Bear astutely pointed out, if the company is using its free cash flow to buy back shares at this rich multiple, management's capital allocation discipline is questionable.

That being said, I have to factor in my past mistakes with this exact type of setup. In a previous review of Agilent (when it was trading lower but still looked "fully valued" around 25x earnings), I leaned too heavily on a static intrinsic value model and completely dismissed the stock's technical repair phase. I issued a cautious rating, and the stock promptly rallied 10% to 17% in a month. The critical lesson I learned is that we cannot use a 10-year valuation discipline as a blunt instrument to time a 30-day or 3-month market outcome. High-quality companies pulling out of a cyclical drawdown often experience strong market re-ratings well before the fundamentals look "cheap."

Therefore, my selective contrarian take today is that while Agilent is too expensive to back up the truck for a new, massive long-term value position, its underlying quality and current momentum mean the market is willing to pay a premium. We shouldn't fight the tape just because the reverse-DCF looks tight. We use the rich valuation to cap our conviction and limit our sizing, but we respect the recovery.

Monitoring Plan To ensure this thesis remains on track over the next 1 to 4 quarters, we need to watch a few specific items. First, we must monitor biopharma capex and end-market demand, specifically looking for signs of a turnaround in the Chinese market. If China remains a structural drag, the 9-10% implied growth rate will be impossible to hit. Second, we need to track the resilience of their consumables and services revenue. If instrument sales remain cyclical, the recurring revenue side must carry the load to prove the "razor/blade" moat is truly protective. Third, we must keep a hawk's eye on management's capital allocation. If they accelerate share repurchases at 30x earnings instead of finding higher-return reinvestment opportunities or paying down debt, it will be a red flag for shareholder value destruction. Finally, we will monitor margin stability; if gross margins start slipping from that 52% level, it signals that the "feature war" commoditization the Bear warned about is eroding their pricing power.

Taking all of this into account-respecting the exceptional business quality, acknowledging the stretched valuation, and applying our past lessons regarding market momentum in premium franchises-my final stance is WATCH.

Value Investing Team Commentary#

The Investor translates the research view into an investment thesis before risk review. This is still not the final stance.

In evaluating Agilent Technologies (A), we are looking at a "wonderful business" currently sporting a "speculative price." From a Buffett-style perspective, Agilent satisfies nearly every qualitative checkbox for a long-term compounder: it possesses a wide economic moat, high switching costs, and generates attractive returns on invested capital (ROIC) of 16.2%. However, the current market configuration challenges the "Margin of Safety" principle that is the bedrock of our discipline.

1. Business Quality and the "Toll Bridge" Moat#

Agilent's primary strength is not just its hardware, but its integration into the scientific workflow. When a pharmaceutical company validates a drug manufacturing process with the FDA using Agilent's liquid chromatography or mass spectrometry systems, that instrument becomes a "toll bridge." Replacing it involves not just the cost of a new machine, but the massive regulatory burden of re-validating the entire process. This leads to the 52.4% gross margin and a high percentage of recurring revenue from consumables and services. As Buffett often notes, the best business is one where you don't have to "reinvent the wheel" every morning; Agilent's installed base does the selling for them.

2. The Valuation Wall: Reverse-DCF and the Growth Gap#

The fundamental friction here is the 30x P/E ratio. Applying a reverse-DCF (Discounted Cash Flow) analysis, a 30x multiple implies that the market is pricing in a perpetual growth rate of approximately 9-10%. Historically, Agilent has been a mid-single-digit organic grower. While the shift toward "asset-light" software and higher-margin diagnostics is a positive tailwind, there is a significant delta between historical performance and the growth expectations embedded in the $149 price tag.

Furthermore, we must be critical of management's capital allocation. If a company earns a 19.3% ROE, it is a productive engine. However, if management uses that cash to buy back shares at 30x earnings (an earnings yield of roughly 3.3%), they are essentially buying an asset with a lower return than their own internal operations. As owners, we prefer management to reinvest in high-ROIC R&D or wait for a more opportunistic price for repurchases.

3. Selective Contrarian Thinking: The "China" and "Capex" Narrative#

The market is currently euphoric about a "summer recovery" and a potential bottoming out of the biopharma capex cycle. The contrarian question we must ask is: What if the slowdown in China is structural rather than cyclical? If Chinese domestic competitors are beginning to erode Agilent's mid-tier market share, the premium multiple is at risk of a permanent de-rating. While the technical "tape" looks strong, a value investor knows that price momentum is a fickle friend if the underlying earnings power fails to accelerate to match the multiple.

4. Integrating Lessons Learned#

We have seen in the past that quality franchises like Agilent can trade at "fair" to "expensive" prices for years without ever becoming "cheap" in a Ben Graham sense. Staying on the sidelines during the recent +17% recovery move was a reminder that quality-scaled margin of safety is different for a wide-moat compounder than for a cyclical commodity business. For Agilent, a 10-15% discount to intrinsic value is a gift, whereas for a lesser business, we would demand 30%. At $149, we are currently at or slightly above our estimate of intrinsic value, leaving no room for error.

Final Assessment#

Agilent is a premier business that we would be proud to own for a decade. However, the current entry point lacks the disciplined margin of safety required for a new large-scale commitment. We respect the business's durability and the current technical momentum, but we refuse to overpay for growth that has not yet materialized in the cash flow statements. We will wait for a "fat pitch"-a temporary earnings miss or a macro-driven sell-off-that brings the price back toward a more reasonable 22-24x multiple.

ANALYST STANCE: WATCH

Deep Values Commentary#

The Risk Management Team debates and the Risk Judge provides the final action-free verdict. This section determines the final ADVOCATE / WATCH / AVOID stance.

Final Stance Scorecard#

This scorecard converts the final research view into a weighted decision frame. It does not replace the narrative judgement, but it makes the main drivers of the verdict easier to scan.

Key Takeaways#

The weighted score lands at 2.83 / 5.0, while the final stance remains WATCH. This is useful as a quick calibration aid rather than a mechanical signal.

Risk Summary#

Higher scores indicate more risk pressure. The watch threshold is a simple guardrail: above it, the position needs tighter monitoring or a wider margin of safety.

Key Takeaways#

This view helps readers separate where the risk sits: valuation, business quality, balance sheet, or growth durability. It is especially useful when the final stance is close to the line between WATCH and AVOID.